$40.42
1.51%
NYSE, Nov 18, 03:59 pm EST. Closed.
ISIN
CH1430134226
Symbol
AMRZ
Index
SMI
Sector

Amrize Target price 2026 - Analyst rating & recommendation

Amrize Classifications & Recommendation

Buy
57%
Hold
37%
Sell
7%

Amrize Price Target

Target Price $47.94
Price $40.41
Potential 18.63%
Number of Estimates 25
25 Analysts have issued a price target Amrize 2027 . The average Amrize target price is $47.94. This is 18.63% higher than the current stock price. The highest price target is $63.00 55.90% , the lowest is $32.32 20.02% .
A rating was issued by 30 analysts: 17 Analysts recommend Amrize to buy, 11 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Amrize stock has an average upside potential 2027 of 18.63% . Most analysts recommend the Amrize stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Revenue Billion $ ??? ???
??? ???
EBITDA Margin ??? ???
??? ???
Net Margin ??? ???
??? ???

27 Analysts have issued a sales forecast Amrize 2026 . The average Amrize sales estimate is

. This is than the revenue of the last 12 months(TTM). The highest sales forecast is , the lowest is .

This results in the following potential growth metrics:

Revenue Estimates

2025 $11.8b 0.95%
2026
2027
2028
2029
2030
2031
2032
2033

25 Analysts have issued an Amrize EBITDA forecast 2026. The average Amrize EBITDA estimate is

. This is than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is , the lowest is .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $2.8b 6.47%
2026
2027
2028
2029
2030
2031
2032
2033

EBITDA Margin

2025 23.87% 7.35%
2026
2027
2028
2029
2030
2031
2032
2033

26 Amrize Analysts have issued a net profit forecast 2026. The average Amrize net profit estimate is

. This is than the net profit for the last 12 months(TTM). The highest net profit forecast is , the lowest is .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2025 $1.2b 6.99%
2026
2027
2028
2029
2030
2031
2032
2033

Net Margin

2025 10.03% 7.86%
2026
2027
2028
2029
2030
2031
2032
2033

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Sign up for free to unlock analyst estimates. Sign up for free

Select at least one metric to display the chart.


Dec '25 2026
Estimates
Earnings Per Share $ ??? ???
??? ???
P/E ???
EV/Sales ???

26 Analysts have issued a Amrize forecast for earnings per share. The average Amrize EPS is

. This is than earnings per share in the financial year 2025. The highest EPS forecast is , the lowest is .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $2.14 6.96%
2026
2027
2028
2029
2030
2031
2032
2033

P/E ratio

Current
2026
2027
2028
2029
2030
2031
2032
2033

Based on analysts' sales estimates for 2026, the Amrize stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.29
2026
2027
2028
2029
2030
2031
2032
2033

P/S ratio

Current
2026
2027
2028
2029
2030
2031
2032
2033

Current Amrize Upgrades & Downgrades

Analyst Rating Action Date
Jefferies
Hold
➜
Underperform
Downgrade Nov 16 2026
UBS
Neutral
➜
Neutral
Unchanged Nov 16 2026
Oppenheimer
Outperform
➜
Outperform
Unchanged Nov 02 2026
DA Davidson
Neutral
➜
Neutral
Unchanged Oct 30 2026
Wells Fargo
Equal-Weight
➜
Equal-Weight
Unchanged Oct 30 2026
Barclays
Equal-Weight
➜
Equal-Weight
Unchanged Oct 19 2026
JP Morgan
Neutral
➜
Neutral
Unchanged Oct 13 2026
Analyst Rating Date
Downgrade
Jefferies:
Hold
➜
Underperform
Nov 16 2026
Unchanged
UBS:
Neutral
➜
Neutral
Nov 16 2026
Unchanged
Oppenheimer:
Outperform
➜
Outperform
Nov 02 2026
Unchanged
DA Davidson:
Neutral
➜
Neutral
Oct 30 2026
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
Oct 30 2026
Unchanged
Barclays:
Equal-Weight
➜
Equal-Weight
Oct 19 2026
Unchanged
JP Morgan:
Neutral
➜
Neutral
Oct 13 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today